This medicine is now known as tanziertib.

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in January 2018 on request of the sponsor.

On 15 October 2014, orphan designation (EU/3/14/1335) was granted by the European Commission to Almirall S.A., Spain, for (S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile for the treatment of pemphigus.

Key facts

Active substance
(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile (tanziertib)
Disease / condition
Treatment of pemphigus
Date of decision
Orphan decision number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Almirall S.A.
Ronda General Mitre, 151
08022 Barcelona
Tel. +34 93 291 31 90
Fax +34 93 291 35 31

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating